Cannabix Technologies to Test Contactless Alcohol Breathalyzer (CAB) in Montana
Cannabix has developed a contactless alcohol breathalyzer for employers and vehicles
VANCOUVER, British Columbia, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Cannabix Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the “Company or Cannabix”) developer of breath testing devices for law enforcement and the workplace reports that Friedel, LLC (“Friedel Clinic”) based in Montana will commence piloting Cannabix’s Contactless Alcohol Breathalyzer (“CAB”). In the fall of 2022, the Company developed its CAB technology for workplaces and vehicles that consist of wall-mounted and in-vehicle versions. The Friedel Clinic has a robust drug testing operation and is one of the top drug testing providers to employers within the state of Montana. The high-volume clinic has a diverse range of patients and focuses on private sector testing for alcohol and illicit drugs. The Friedel Clinic has extensive experience piloting with new alcohol and drug testing technologies. Video of the CAB device can be viewed at .
Montana Senator Chris Friedel stated, “The Friedel Clinic has been a pioneer in alcohol, drug and brain health testing in the state of Montana. We have tremendous amount of experience with a range of new testing and monitoring equipment. In addition, we are excited to see how the Cannabix Contactless Alcohol Breathalyzer devices can enhance safety in both workplace and in-vehicle settings – in particular the potential to disrupt legacy alcohol interlock methods which have seen little innovation over the last 40 years.”
The wall mounted CAB would be targeted for employers needing to deploy a pre-access test for alcohol consumption before and during work hours in a fast and cost-effective way. The CAB technology allows for a user to direct a single breath sample towards a small orifice integrated into a wall mounted unit (for indoor use) and behind the steering wheel for in-cabin vehicle use – in a completely contactless manner. The CAB is fundamentally different than existing alcohol breathalyzers and interlock systems that require users to use a mouthpiece or straw and directly blow into a handheld device that is connected to the vehicle usually with a cable. The Cannabix CAB could be integrated into various locations in the vehicle cabin. The CAB provides a warning, pass or fail result along with a Blood Alcohol Content (BAC) level on the screen for the driver to see. This kind of technology holds potential to be integrated with interlock systems and be used in various settings including automotive, heavy-duty equipment, heavy transport vehicles, watercraft and motorbikes. Furthermore, the device could be used in bars, restaurants and hotels for both patrons and employees.
Vehicle Alcohol Breath Screening
The Company has developed its CAB technology in response to interest in new vehicle alcohol detection technologies. In September 2022, the National Transportation Safety Board (NTSB) issued a recommendation that all new vehicles be equipped with technology that would prevent a person impaired by alcohol from driving (1). In November 2021, the U.S. House of Representatives, passed the Infrastructure Investment and Jobs Act (IIJA) which called for new cars to come equipped with technology that will detect alcohol in breath. The legislation directed the National Highway Traffic Safety Administration to set new safety standards within three years for impaired driving safety equipment on all new vehicles (2) (3).
Manufacturers such as Volvo have experimented with offering alcohol-detection systems as optional equipment.
(1)
(2)
(3)
Readers are advised that, although the Company has achieved proof of concept prototype for the CAB, the testing method and device is still in the preapproval stage and accordingly the Company is not currently making any express or implied claims that the technology will proceed to commercial use.
About Cannabix Technologies Inc.
Cannabix Technologies Inc. is a developer of marijuana breathalyzer technologies for law enforcement and the workplace. Cannabix is working to develop drug-screening devices that will detect THC - the psychoactive component of marijuana that causes impairment using breath samples. Breath testing for THC would allow employers and law enforcement to identify recent marijuana use that better aligns with impairment. Cannabix devices are in the advanced prototype and pre-clinical testing stage.
We seek Safe Harbor.
On behalf of the Board of Directors
“Rav Mlait”
CEO
Cannabix Technologies Inc.
For further information, contact the Company at
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (iv) the ability of the Company to develop and market its future product; and (v) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that its development of breathalyzer technology will provide any benefit to the Company, and no assurance that any proposed new products will be built, will be successful in beta testing or clinical trials. The is no assurance that the Company will enter into any partnerships to advance any of its corporate initiatives or technologies. There is no assurance that any “patent pending” or “provisional patents” technologies licensed by the Company or owned by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.
A photo accompanying this announcement is available at
